Welcome to NeRRe Therapeutics
Developing a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe is continuing development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF).
A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments for it. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA.
NeRRe Therapeutics is led by CEO Mary Kerr and an experienced management team who sold a sister NK antagonist company KaNDy Therapeutics to Bayer in 2020 for $425m up front and a total potential deal value in excess of $1b (Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd). This team is committed to unlocking the significant potential of orvepitant in IPF cough.
Working with experienced partners to delivery groundbreaking services.
NeRRe is backed by international life sciences investors: Advent Life Sciences, Columbus Venture Partners, Forbion Capital Partners, Fountain Healthcare Partners and OrbiMed Advisors.
The company was founded in 2012 as a spin out from GSK, which transferred its NK antagonist portfolio, and all associated intellectual property to NeRRe. The company has since generated exciting new preclinical and clinical data to support the progression of its lead clinical asset orvepitant and created further value with novel intellectual property.
Latest News & Events
Dr Steve Pawsey, CMO at NeRRe Therapeutics to present at the 9th American Cough Conference
Dr Steve Pawsey, CMO at NeRRe Therapeutics to present at the 9th American Cough Conference Dr Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics to present at the 9th American…
Read More
NeRRe Therapeutics raises £20 million in a Series B2 financing round
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF).…
Read More
Dr Steve Pawsey, CMO at NeRRe Therapeutics to Present at The Eleventh International Cough Symposium
Dr Steve Pawsey, Chief Medical Officer at NeRRe Therapeutics to Present at The Eleventh International Cough Symposium Virtual Event, 21 - 22 January 2021, London, UK Steve will be presenting…
Read More
